跳至主要内容
临床试验/NCT01398098
NCT01398098已完成2 期

Gastric Emptying Time Assessment During Bowel Preparation With COLOKIT®

Laboratoires Mayoly Spindler1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2011年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
30
试验地点
1
主要终点
Percentage of patients with a residual antral volume lower than 20 mL

研究概览

简要总结

Ultra-sound study to assess changes in intragastric volume after bowel preparation.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subject who signed an informed consent to participate in the trial.
  • Subject affiliated with Social Security
  • Men and women aged 18 to 75 years.
  • Subject with an indication of scheduled outpatient colonoscopy.
  • colonoscopy performed within six hours after the second sequence COLOKIT®.
  • Subject able to swallow tablets.

排除标准

  • Women pregnant or likely to be (without contraception) or nursing.
  • Subject having any of the following diseases or conditions:
  • allergy or hypersensitivity to the product tested or any of its excipients,
  • nausea, vomiting or abdominal pain,
  • clinically significant renal failure,
  • primary hyperparathyroidism associated with hypercalcemia,
  • congestive heart failure,
  • a known or suspected bowel obstruction,
  • megacolon (congenital or acquired)
  • intestinal perforation,
  • an inflammatory disease or suspected inflammatory bowel disease,
  • swallowing disorders,
  • known digestive motor disorders (gastroparesis, scleroderma, mega-esophagus),
  • diabetes mellitus (insulin or non insulin-dependent)
  • a history of gastric surgery (partial or total)
  • a contraindication to the anesthesia required for the completion of the colonoscopy,
  • Any clinical condition which, in the opinion of the investigator, would not allow the subject to perform the test in good conditions.

研究组 & 干预措施

COLOKIT®

Experimental

干预措施: Sodium phosphate (Drug)

结局指标

主要结局

Percentage of patients with a residual antral volume lower than 20 mL

时间窗: after 2nd treatment regimen intake

次要结局

  • Adverse events(After drug intake)
  • Acceptability of COLOKIT®.(After drug intake)
  • Colonoscopy results(After colonoscopy.)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验